Therapeutic area intelligence for Immunomodulator with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 1

Companies

Lupin →

Assets

Recent signals(4)

RegulatoryJuly 6, 2026

FDA Accepts Supplement Application for Lenalidomide by Apotex

The FDA has accepted a supplemental application for lenalidomide submitted by Apotex.

StrategyJuly 6, 2026

Lupin's Lenalidomide ANDA214398 Receives Abbreviated Approval

Lupin has received abbreviated approval for its ANDA214398 application for Lenalidomide.

RegulatoryJuly 6, 2026

FDA Acceptance of POMALIDOMIDE Supplement by Breckenridge

The FDA has accepted the supplemental application for POMALIDOMIDE submitted by Breckenridge.

StrategyJuly 6, 2026

FDA Grants Approval for Thalidomide ANDA213267 by NATCO

The FDA has granted approval for ANDA213267, a generic version of Thalidomide, submitted by NATCO.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.